[Dynamics of the soluble CD50-antigen level in patients with breast cancer in the course of combined therapy].
Immune enzyme assay with polyclonal and monoclonal antibodies was made use of to investigate the dynamic changes of soluble CD50-antigen in patients with breast cancer during chemotherapy and surgical treatment. A dependence of the content of the above antibody on a variety of parameters characterizing the tumor process and patients age was detected. The determination of a dynamic level of this protein provides for evaluating the efficiency of a treatment scheme.